Previous 10 | Next 10 |
2023-11-27 11:23:02 ET Summary SunPower is a Seeking Alpha Quant “strong sell,” with 36.9% of the shares shorted. SunPower is majority-owned (50.7%) by TotalEnergies and it has a strong presence in the US domestic solar and energy management scene. Notwithstandin...
2023-11-21 13:10:50 ET DENVER, Colo., Nov. 20, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; ProKidney Corp (NASDAQ: PROK), Can Fite Biofarma Ltd (AMEX: CANF), Seres Therapeutics Inc (NASDAQ: MCR...
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics PR Newswire Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trilli...
2023-11-20 12:59:05 ET Gainers: Mira Pharmaceuticals ( MIRA ) +58% . YPF ADR ( YPF ) +39% . Altamira Therapeutics Ltd ( CYTO ) +39% . ProKidney Corp ( PROK ) +35% . Soluna Holdings ( SLNH ) +32% . Safety Shot ( SHOT ) +...
2023-11-12 02:01:12 ET Summary Considering current Seres valuation and Q3 update risk-reward has improved considerably. However, pending more updates on commercial uptake of VOWST and payer coverage risk remains high. Restructuring, including reduction of workforce by 41% and paus...
2023-11-12 01:53:51 ET Summary Seres's FDA-approved Vowst faces commercial challenges despite clinical success, impacting financials with increased losses and share dilution. Despite a decent cash runway, Seres's stockholders' deficit and substantial long-term liabilities suggest ...
2023-11-04 11:52:09 ET Seres Therapeutics, Inc. (MCRB) Q3 2023 Results Conference Call November 02, 2023 08:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference...
2023-11-02 13:15:49 ET More on etc. Dynatrace, Inc. (DT) Q2 2024 Earnings Call Transcript Geron Corporation 2023 Q3 - Results - Earnings Call Presentation Gates Industrial: Encouraging Q3 Report Needed To Finally Create A Floor For The Stock Icahn Enterprises...
2023-11-02 08:10:36 ET More on Seres Therapeutics Seres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High Price Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Ca...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
News, Short Squeeze, Breakout and More Instantly...
Seres Therapeutics Inc. Company Name:
MCRB Stock Symbol:
NASDAQ Market:
Seres Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 12.2% to $0.6106 on volume of 413,566,315 shares Trinity Place Holdings Inc. (TPHS) rose 44.6% to $0.1756 on volume of 351,549,876 shares Presto Automation Inc. (PRST) rose 17.4% to...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 37.2% to $0.7466 on volume of 94,759,512 shares GameStop Corporation (GME) rose 0.0% to $46.5702 on volume of 64,189,668 shares Trinity Place Holdings Inc. (TPHS) rose 126.9% to $0....
2024-06-07 09:15:02 ET Oppenheimer analyst issues PERFORM recommendation for MCRB on June 7, 2024 07:37AM ET. The previous analyst recommendation was Outperform. MCRB was trading at $0.8531 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...